Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy

Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Blau O, Blau IW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/f7c42ffbee1548d38a5eef86dd4c05f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7c42ffbee1548d38a5eef86dd4c05f0
record_format	dspace
spelling	oai:doaj.org-article:f7c42ffbee1548d38a5eef86dd4c05f02021-12-02T00:54:34ZSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy1178-6957https://doaj.org/article/f7c42ffbee1548d38a5eef86dd4c05f02014-12-01T00:00:00Zhttp://www.dovepress.com/some-aspects-of-allogeneic-stem-cell-transplantation-in-patients-with--peer-reviewed-article-SCCAAhttps://doaj.org/toc/1178-6957 Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant modalities of different intensities and alternative donor sources are now in use. Current advances in transplant technology are allowing the consideration of older patients. This should result in a greater number of older patients benefiting from this potentially curative treatment modality. Despite advances in transplantation technology, there is still considerable morbidity and mortality associated with this approach. Nevertheless, with the introduction of reduced-intensity conditioning and thereby reduced early mortality, transplant numbers in MDS patients have significantly increased. Moreover, recent new developments with innovative drugs, including hypomethylating agents, have extended the therapeutic alternatives for MDS patients. Hypomethylating agents allow the delay of allogeneic stem cell transplantation by serving as an effective and well-tolerated means to reduce disease burden. Keywords: myelodysplastic syndrome, allogeneic stem cell transplantation, reduced-intensity conditioningBlau OBlau IWDove Medical PressarticleCytologyQH573-671ENStem Cells and Cloning: Advances and Applications, Vol 2014, Iss default, Pp 101-108 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Blau O Blau IW Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
description	Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant modalities of different intensities and alternative donor sources are now in use. Current advances in transplant technology are allowing the consideration of older patients. This should result in a greater number of older patients benefiting from this potentially curative treatment modality. Despite advances in transplantation technology, there is still considerable morbidity and mortality associated with this approach. Nevertheless, with the introduction of reduced-intensity conditioning and thereby reduced early mortality, transplant numbers in MDS patients have significantly increased. Moreover, recent new developments with innovative drugs, including hypomethylating agents, have extended the therapeutic alternatives for MDS patients. Hypomethylating agents allow the delay of allogeneic stem cell transplantation by serving as an effective and well-tolerated means to reduce disease burden. Keywords: myelodysplastic syndrome, allogeneic stem cell transplantation, reduced-intensity conditioning
format	article
author	Blau O Blau IW
author_facet	Blau O Blau IW
author_sort	Blau O
title	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
title_short	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
title_full	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
title_fullStr	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
title_full_unstemmed	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
title_sort	some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/f7c42ffbee1548d38a5eef86dd4c05f0
work_keys_str_mv	AT blauo someaspectsofallogeneicstemcelltransplantationinpatientswithmyelodysplasticsyndromeadvancesandcontroversy AT blauiw someaspectsofallogeneicstemcelltransplantationinpatientswithmyelodysplasticsyndromeadvancesandcontroversy
_version_	1718403472219439104

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy

Ejemplares similares